|
Idebenone
Idebenone increases nerve growth factor (NGF) in the brain.
Idebenone is a powerful antioxidant and positively affects brain chemistry.
Idebenone has been shown to promote information transfer across the corpus callosum, the membrane separating the right and left brain hemispheres.
Idebenone has been used to treat Alzheimer's and to lessen damage from strokes.
Idebenone can increase production of the brain neurotransmitters serotonin, dopamine, adrenalin, and noradrenanlin.
Who can benefit from Idebenone?
idebenone
article
to
order
1. People desiring improved mental functioning.
2. Stroke victims.
3. Alzheimer's patients.
4. Those preparing for major surgery.
5. People with heart energetics problems, e.g. cardiomyopathy, congestive heart failure
6. People with myelination problems, e.g. multiple sclerosis.
7. Athletes with high endurance requirements such as marathoners, cyclists, etc
8. People wishing to enhance the brain serotonin benefits of SSRI's, (Prozac, Paxil)
9. Those suffering liver damage from toxic chemicals or hepatitis.
Idebenone cream will be available in 2004 from Allergan, the company
that introduced Botox.
Research
www.idebenone.org
Weyer
G, Babeji-Dolle RM, Hadler D, Hofmann S, Herrmann WM, "A controlled study
of 2 doses of idebenone in the treatment of Alzheimer's disease." Neuropsychobiology
1997; 36(2):73-82
Ranen
NG and colleagues, "A controlled trial of idebenone in Huntington's
disease" Mov Disord 1996 Sep; 11(5):549-554
Ikejiri
Y, Mori E, Ishii K, Yasuda M, Sasaki M, "Idebenone improves cerebral
mitochondrial oxidative metabolism in a patient with MELAS" Neurology
1996; Aug 47(2); 583-585.
Pisano
P and colleagues, "Plasma concentrations and pharmacokinetics of idebenone
and its metabolites following single and repeated doses in young patients with
mitochondrial encephalomyopathy." Eur J Pharmacol 1996;
51(2):167-169.
Gillis
JC, Benefield P, McTavish D, "Idebenone, a review of its pharmacodynamic
and pharmacokinetic properties, and therapeutic use in age-related cognitive
disorders." Drugs Aging 1994; Aug;5 (2): 133-152.
Bergamasco
B, Scarzella L, "Idebenone, a
new drug in the treatment of cognitive impariment in patients with dementia of
the Alzheimer type." Funct Neurol 1994; May;9(3):161-168.
Nitta
A, Hasegawa T, "Oral
administration of idebenone, a stimulator of NGF synthesis recovers reduced NGF
content in aged rat brain." Neuosci Lett 1993 Dec 12;
163(2):219-222.
Suno
M, Nagaoka A, "Inhibition of brain mitochondrial swelling by
idebenone."
Arch Gerontol Geriatr 1989 May; 8(3):299-305.
Ihara Y, Namba S, Shiraba T, "Mitochondrial
encephalomyopathy (MELAS), pathological study and successful therapy with
coenzyme Q10 and idebenone." J Neurol Sci 1989 May; 90(3):263-271.
Lerman-Sagie T, Rustin P, Lev D, "Dramatic improvement
in mitochondrial cardiomyopathy following treatment with idebenone."
J Inherit Metab Dis 2001 Feb;24(1):28-34.
Gutzmann H, Hadler D., "Sustained efficacy and
safety of idebenone in the treatment of
Alzheimer's disease: update on a 2-year double-blind multicentre study."
J Neural Transm Suppl 1998;54:301-10.
Yamada K, Nitta A, Hasegawa T, "Orally active NGF synthesis stimulators:
potential therapeutic agents in Alzheimer's disease."
Behav Brain Res 1997 Feb;83(1-2):117-22.
Bergamasco B, Scarzella L, "Idebenone, a new drug
in the treatment of cognitive impairment in patients with dementia of the
Alzheimer type."
Funct Neurol 1994 May-Jun;9(3):161-8.
|
